These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28286235)

  • 41. Combination activity of neuraminidase inhibitor oseltamivir and α-tocopherol in influenza virus A (H3N2) infection in mice.
    Galabov AS; Mileva M; Simeonova L; Gegova G
    Antivir Chem Chemother; 2015 Aug; 24(3-4):83-91. PubMed ID: 27341844
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mammalian pathogenesis of oseltamivir-resistant pandemic (H1N1) 2009 influenza virus isolated in South Korea.
    Kwon D; Shin K; Kim SJ; Lee JY; Kang C
    Virus Res; 2014 Jun; 185():41-6. PubMed ID: 24657788
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
    Bantia S; Parker CD; Ananth SL; Horn LL; Andries K; Chand P; Kotian PL; Dehghani A; El-Kattan Y; Lin T; Hutchison TL; Montgomery JA; Kellog DL; Babu YS
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1162-7. PubMed ID: 11257030
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined administration of oseltamivir and hochu-ekki-to (TJ-41) dramatically decreases the viral load in lungs of senescence-accelerated mice during influenza virus infection.
    Ohgitani E; Kita M; Mazda O; Imanishi J
    Arch Virol; 2014 Feb; 159(2):267-75. PubMed ID: 23979178
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality.
    Marjuki H; Mishin VP; Chesnokov AP; De La Cruz JA; Fry AM; Villanueva J; Gubareva LV
    J Infect Dis; 2014 Aug; 210(3):435-40. PubMed ID: 24569063
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models.
    Fukao K; Ando Y; Noshi T; Kitano M; Noda T; Kawai M; Yoshida R; Sato A; Shishido T; Naito A
    PLoS One; 2019; 14(5):e0217307. PubMed ID: 31107922
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oseltamivir inhibits H7 influenza virus replication in mice inoculated by the ocular route.
    Belser JA; Sleeman K; Pearce MB; Katz JM; Gubareva LV; Tumpey TM
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1616-8. PubMed ID: 22155827
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil.
    Kiso M; Yamayoshi S; Furusawa Y; Imai M; Kawaoka Y
    Viruses; 2019 Nov; 11(11):. PubMed ID: 31731678
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Salinomycin Inhibits Influenza Virus Infection by Disrupting Endosomal Acidification and Viral Matrix Protein 2 Function.
    Jang Y; Shin JS; Yoon YS; Go YY; Lee HW; Kwon OS; Park S; Park MS; Kim M
    J Virol; 2018 Dec; 92(24):. PubMed ID: 30282713
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mixtures of oseltamivir-sensitive and -resistant pandemic influenza A/H1N1/2009 viruses in immunocompromised hospitalized children.
    Suhaila M; Tang JW; Lee HK; Lin C; Tambyah PA; Yap HK; Quak SH; Koay ES
    Pediatr Infect Dis J; 2011 Jul; 30(7):625-7. PubMed ID: 21206398
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Anti-viral activity of a complex of the glycyrrhizic acid-alpha-glutamyltryptophan against the experimental lethal influenza infection in white mice caused by the oseltamivir-resistant strain of the virus].
    Smirnov VS; Garshinina AV; Shtro AA; Anikin VB; Galochkina AV; Beliavskaia SV; Zarubaev VV
    Vopr Virusol; 2014; 59(5):31-8. PubMed ID: 25895209
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tamiphosphor monoesters as effective anti-influenza agents.
    Chen CL; Lin TC; Wang SY; Shie JJ; Tsai KC; Cheng YS; Jan JT; Lin CJ; Fang JM; Wong CH
    Eur J Med Chem; 2014 Jun; 81():106-18. PubMed ID: 24836064
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery of potential drugs for human-infecting H7N9 virus containing R294K mutation.
    He JY; Li C; Wu G
    Drug Des Devel Ther; 2014; 8():2377-90. PubMed ID: 25489236
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prophylactic and therapeutic combination effects of rimantadine and oseltamivir against influenza virus A (H3N2) infection in mice.
    Simeonova L; Gegova G; Galabov AS
    Antiviral Res; 2012 Aug; 95(2):172-81. PubMed ID: 22617756
    [TBL] [Abstract][Full Text] [Related]  

  • 55. H1N1 influenza A virus neuraminidase modulates infectivity in mice.
    Ferraris O; Escuret V; Bouscambert M; Casalegno JS; Jacquot F; Raoul H; Caro V; Valette M; Lina B; Ottmann M
    Antiviral Res; 2012 Mar; 93(3):374-80. PubMed ID: 22321413
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A comparison of pyrosequencing and neuraminidase inhibition assays for the detection of oseltamivir-resistant pandemic influenza A(H1N1) 2009 viruses.
    Deng YM; Caldwell N; Hurt A; Shaw T; Kelso A; Chidlow G; Williams S; Smith D; Barr I
    Antiviral Res; 2011 Apr; 90(1):87-91. PubMed ID: 21376084
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States.
    Dharan NJ; Gubareva LV; Meyer JJ; Okomo-Adhiambo M; McClinton RC; Marshall SA; St George K; Epperson S; Brammer L; Klimov AI; Bresee JS; Fry AM;
    JAMA; 2009 Mar; 301(10):1034-41. PubMed ID: 19255110
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oseltamivir boosts 2009 H1N1 virus infectivity in vitro.
    Lin X; Zhou J; Zhang Y; Wu J; Zhang F; Li Z; Zhang Y; Bi S; Shu Y; Wang Y
    Biochem Biophys Res Commun; 2009 Dec; 390(4):1305-8. PubMed ID: 19879239
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Utilization of alpha-1-acid glycoprotein levels in the serum as a parameter for in vivo assay of influenza virus inhibitors.
    Sidwell RW; Wong MH; Bailey KW; Barnard DL; Jackson MK; Smee DF
    Antivir Chem Chemother; 2001 Nov; 12(6):359-65. PubMed ID: 12018681
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir.
    Leiva-Juarez MM; Kirkpatrick CT; Gilbert BE; Scott B; Tuvim MJ; Dickey BF; Evans SE; Markesich D
    Eur J Pharmacol; 2018 Jan; 818():191-197. PubMed ID: 29066417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.